## MDT: Medtronic plc - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -0.1% below STRENGTH zone (3.0-6.0%); PEG 3.69 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($93.33)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Lazard Freres Gestion S.A.S. Boosts Stock Position in Medtronic PLC $MDT**
- Source: MarketBeat | 20260102T124305 | Bullish | Relevance: 100%
- Lazard Freres Gestion S.A.S. increased its stake in Medtronic PLC (NYSE:MDT) by 6.4% in the third quarter of 2025, now holding 1,530,777 shares valued at $145.8 million, making it their 10th largest position. Medtronic reported stronger-than-expected quarterly earnings and revenue, with a positive outlook for FY2026 EPS, and announced a quarterly dividend of $0.71. Institutional investors collectively own 82.06% of the company's stock.

**2. Ascent Group LLC Has $1.63 Million Stock Holdings in Medtronic PLC $MDT**
- Source: MarketBeat | 20260102T090806 | Bullish | Relevance: 100%
- Ascent Group LLC significantly reduced its stake in Medtronic PLC by 55.3% in Q3, now holding 17,137 shares valued at $1.63 million. Medtronic exceeded Q3 earnings estimates with EPS of $1.36 and revenue of $8.96 billion, and has provided FY2026 EPS guidance of $5.620-$5.660. The company, which has a market cap of $123.24 billion and a P/E ratio of 25.91, also declared a quarterly dividend of $0.71, with analysts maintaining a "Moderate Buy" rating and a target price of $109.94.

**3. Medtronic PLC $MDT Shares Acquired by Allspring Global Investments Holdings LLC**
- Source: MarketBeat | 20260101T081556 | Somewhat-Bullish | Relevance: 100%
- Allspring Global Investments Holdings LLC increased its stake in Medtronic PLC by 1.5% in the third quarter, acquiring 17,631 additional shares. Medtronic reported strong Q3 earnings, surpassing expectations with $1.36 EPS and $8.96 billion in revenue, and announced a quarterly dividend of $0.71 per share. The company currently holds a "Moderate Buy" consensus rating from analysts with an average target price of $109.94.

**4. Calamos Advisors LLC Has $51.24 Million Stock Holdings in Medtronic PLC $MDT**
- Source: MarketBeat | 20251231T095806 | Somewhat-Bullish | Relevance: 98%
- Calamos Advisors LLC significantly increased its stake in Medtronic PLC (NYSE:MDT) by 27.9% in Q3, now holding 538,018 shares valued at approximately $51.24 million. Medtronic recently exceeded Q1 earnings expectations and provided a positive FY2026 guidance, while analysts maintain a "Moderate Buy" rating with an average target price near $109.94. The company also declared a quarterly dividend of $0.71 per share, representing an annualized yield of about 2.9%.

**5. Lee Johnson Capital Management LLC Makes New $2.60 Million Investment in Medtronic PLC $MDT**
- Source: MarketBeat | 20251231T121024 | Somewhat-Bullish | Relevance: 97%
- Lee Johnson Capital Management LLC has made a new $2.60 million investment in Medtronic PLC (NYSE:MDT) during the third quarter, acquiring 27,303 shares. The medical technology company has seen strong institutional interest, with hedge funds increasing or initiating positions, and recently beat quarterly earnings expectations with $1.36 EPS and $8.96B revenue. Medtronic also declared a quarterly dividend of $0.71 per share and maintains a "Moderate Buy" consensus rating from analysts.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | Truist Securiti | $107 | $110 | -3% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | Truist Securiti | main | Hold |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 6 ($0.53M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 43.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 9.9% (+0.1%)
- Blackrock Inc.: 9.3% (-2.4%)
- JPMORGAN CHASE & CO: 8.1% (+197.7%)
- State Street Corpora: 4.7% (+1.1%)
- Capital Research Glo: 2.4% (-15.6%)

### Key Risks

1. Valuation stretched: PEG 3.7x requires aggressive growth execution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 3.69 signals overvaluation risk, limited margin of safety. Balance sheet: strong liquidity (2.4x). Analyst sentiment negative (1 target cuts vs 0 raises). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $123.2B |
| Beta | 0.72 |
| 52W Range | $79.55 - $106.33 |
| Short Interest | 1.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.69 |
| Forward P/E | 15.7 |
| Current P/E | 17.0 |
| YoY Growth | 8.2% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -2.3% to -0.1% (+2.3% in 5 days), confirming momentum buildup. Below STRENGTH zone by 3.1pp (needs >3.0% for momentum thesis). MRS_5 turning positive (0.4%) - potential reversal signal. Long-term uptrend intact (above SMA200 at 1.05x) but short-term weakness (below SMA20). OFD pattern: +DBN (Indecision).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -0.07% (CS: 34) | Neutral |
| RSI_14 | 37.9 | Neutral |
| MACD Histogram | -0.45 | Bearish |
| vs SMA20 | 0.975x | Below |
| vs SMA50 | 0.987x | Below |
| vs SMA200 | 1.052x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $96.05
- **Stop Loss:** $93.33 (2.8% risk)
- **Target:** $98.77 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 529
- **Position Value:** $50,810.45
- **Portfolio %:** 50.81%
- **Risk Dollars:** $1,440.00
- **Risk Per Trade:** 1.44%
- **Modifiers:** L1 120% | L2 120% | Combined 1.44x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.20x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with stable risk appetite as 2026 trading begins. VIX at 14.51 (4th percentile) signals complacency while positive yield curve (+65bps) and moderate breadth (53.1%) support continuation. Focus on upcoming jobs data (Jan 9) and earnings season kickoff mid-January for directional catalysts.*

### Earnings

**Next:** 2026-02-17 (Est: $1.34)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q4 | $1.31 | $1.36 | +3.5% |
| 2025Q3 | $1.23 | $1.26 | +2.5% |
| 2025Q2 | $1.58 | $1.62 | +2.7% |
| 2025Q1 | $1.36 | $1.39 | +2.2% |

---
*RULE-based L3 | 2026-01-06 17:52 | MRS_10*